Whether a r/m or not it won't affect Univec's ability to have partnerships with mj facilities to use its transdermal patches. This is my focus for my investment. I don't see UNVC as a 'shell' but a company with a mission and product that can be used in an exploding industry by all those that want and can implement it into their processing system.